Our group specializes in determining the cellular and molecular mechanisms of beneficial effects of mesenchymal stem cells (MSCs) in diseases that include heart disease, diabetes, and peritonitis. The goal is to develop a cellular therapy for human diseases either (a) with adult stem/progenitor cells (MSCs), or (b) with therapeutic factors that MSCs produce in response to signals from injured tissues.